These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 207959)
21. [Treatment of primary hyperlipoproteinemias. Comparison of N 041 with clofibrate]. Gaertner U; Johannes KJ MMW Munch Med Wochenschr; 1976 Sep; 118(36):1127-30. PubMed ID: 184377 [TBL] [Abstract][Full Text] [Related]
22. The treatment of hyperlipoproteinaemia with gemfibrozil compared with placebo and clofibrate. Nye ER; Sutherland WH; Temple Wa N Z Med J; 1980 Nov; 92(671):345-9. PubMed ID: 6935550 [TBL] [Abstract][Full Text] [Related]
23. [Dyslipidemic patients with coronary cardiopathy. Effect of different doses of OMEGA-3 fatty acids on serum lipids and lipoproteins]. Arteaga A; Villanueva CL; Skorin C; Guasch V; Solís de Ovando F; Velasco N; Acosta AM; Leighton F Rev Med Chil; 1993 Jun; 121(6):618-25. PubMed ID: 8278696 [TBL] [Abstract][Full Text] [Related]
24. [Clofibrate therapy in hypercholesterolemia. Reports on medium-long-term movements of HDL- cholesterol by the action of clofibrate]. Mertz DP Fortschr Med; 1980 Dec; 98(45):1761-6. PubMed ID: 7461569 [TBL] [Abstract][Full Text] [Related]
25. Effect of moderate isocaloric modification of dietary carbohydrate on high-density lipoprotein composition and apolipoprotein A-1 turnover in humans. Zimmerman J; Eisenberg S; Kaufmann NA; Fainaru M; Oschry Y; Friedlander Y; Stein Y Isr J Med Sci; 1986 Feb; 22(2):95-104. PubMed ID: 3949491 [TBL] [Abstract][Full Text] [Related]
26. Replacement of carbohydrate by protein in a conventional-fat diet reduces cholesterol and triglyceride concentrations in healthy normolipidemic subjects. Wolfe BM; Piché LA Clin Invest Med; 1999 Aug; 22(4):140-8. PubMed ID: 10497712 [TBL] [Abstract][Full Text] [Related]
27. [Fenofibrate: hypolipaemic activity and safety in long-term treatment. Effects on HDL, LDL, VLDL and apoprotein B in short-term treatment (author's transl)]. Rouffy J; Sauvanet JP; Chanu B; Bakir R; Goy-Loeper J; Saya C; Pinaroli F Nouv Presse Med; 1980 Dec; 9(49):3747-51. PubMed ID: 7208341 [TBL] [Abstract][Full Text] [Related]
28. [Treatment of primary hyperlipoproteinemia type IIb and IV. Comparison of the lipid lowering effect of phenformin, clofibrate, and a combination of both (author's transl)]. Koschinsky T; Lenhard P; Gries FA; Vogelberg KH; Wolfram G; Lang PD; Vollmar J Med Klin; 1977 Sep; 72(38):1537-43. PubMed ID: 904549 [TBL] [Abstract][Full Text] [Related]
29. [Combination of clofibrate and phenformin in the treatment of endogenous hypertriglyceridaemia (author's transl)]. Vogelberg KH Dtsch Med Wochenschr; 1976 Dec; 101(51):1868-71. PubMed ID: 1001205 [TBL] [Abstract][Full Text] [Related]
30. A physician's guide to hyperlipidemia. Fredrickson DS Mod Concepts Cardiovasc Dis; 1972 Jul; 41(7):31-6. PubMed ID: 4343098 [No Abstract] [Full Text] [Related]
31. [Effect of etofylline clofibrate on the composition of lipoproteins in hyperlipidaemia type IIb and IV (author's transl)]. Ditschuneit HH; Hutt V; Klör HU; Ditschuneit H Arzneimittelforschung; 1980; 30(11b):2063-7. PubMed ID: 7194061 [TBL] [Abstract][Full Text] [Related]
32. [Therapy of hyperlipoproteinemia type II with Xantinol-nicotinate (author's transl)]. Haacke H; Parwaresch MR; Mäder C Med Klin; 1977 Jul; 72(27):1183-7. PubMed ID: 196168 [TBL] [Abstract][Full Text] [Related]
33. [Changes in serum lipoproteins in cerebrovascular disease (author's transl)]. Bruck J; Fischer M; Tschabitscher H Wien Klin Wochenschr; 1981 Oct; 93(19):604-9. PubMed ID: 7324470 [TBL] [Abstract][Full Text] [Related]
34. [The therapeutic efficacy of bezafibrate in hyperlipoproteinemias of various types]. Noseda G; Fragiacomo C; Weidmann P; Bachmann C Schweiz Med Wochenschr; 1980 Dec; 110(49):1875-7. PubMed ID: 7455660 [TBL] [Abstract][Full Text] [Related]
35. Effect of colestipol and clofibrate on plasma lipid and lipoproteins in type IIa hyperlipoproteinemia. Hunninghake DB; Probstfield JL; Crow LO; Isaacson SO Metabolism; 1981 Jun; 30(6):605-9. PubMed ID: 7231197 [TBL] [Abstract][Full Text] [Related]
36. [Hyperlipoproteinemia type IIa. Serum lipoprotein pattern as influenced by diet and clofibrate]. Mertz DP; Suermann I; Loewer H; Schmidt GG MMW Munch Med Wochenschr; 1979 Jun; 121(23):791-2. PubMed ID: 223044 [No Abstract] [Full Text] [Related]
37. [Effect of diet and drug therapy on the level of high density lipoprotein cholesterol in patients with primary hyperlipoproteinemia]. Padosh D; Kustosh D; Puchok I; Dem'ianova N; Audikovski M Klin Med (Mosk); 1981 Sep; 59(9):45-8. PubMed ID: 7311430 [No Abstract] [Full Text] [Related]
38. [The relationship of cholesterol (CHO) and triglycerides (TG) in VLDL, LDL, and VLDL subfractions by agarose gel electrophoresis, using CHO and TG dual staining (AG-CHO, TG staining)]. Miyake N; Iizuka K Rinsho Byori; 2002 Jun; 50(6):605-12. PubMed ID: 12166081 [TBL] [Abstract][Full Text] [Related]
39. Treatment of hyperlipoproteinemia type II with etofibrate. Gustafson A Int J Clin Pharmacol Biopharm; 1979 Dec; 17(12):498-502. PubMed ID: 528096 [TBL] [Abstract][Full Text] [Related]
40. Atilipidemic drugs. Part 5: Evaluation of the hypolipidemic effect of LF 178 in 191 patients affected by the atherogenic form of endogenous hyperlipoproteinemia (types IIa, IIb and IV). Rouffy J; Dreux C; Goussault Y; Dakkak R; Renson FJ Arzneimittelforschung; 1976; 26(5):901-6. PubMed ID: 183788 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]